The chambers are particularly helpful when
studying allergy immunotherapies—a new
class of allergen-specific medications that
target allergy mechanisms. Dr. Salapatek
and her team are in the process of test-
ing an allergen-specific therapy for grass.
The problem is this: most people are not
allergic simply to one thing. EEC technol-
ogy allows the team to expose patients to
only grass-related allergens in order to test
the efficacy of the therapy. The project is
the first of its kind in the world, using over
250 patients and 20 clinical investigators,
and mobile EECs — transportable units,
where everything needed to carry out the
study can be packed up into an intermodal
container. The chamber itself is an inflat-
able system. With two installations in Cin-
cinnati and New Jersey, the company is
doing the world’s first multi-centre mobile
chamber study across the U.S. right now.
Having worked with clients and spon-
sors across Canada, the U.S., Europe and
South Africa, Inflamax is now planning to
conduct EEC studies in Japan towards ad-
dressing the Japanese government’s call
to develop new allergy medications to deal
with the high level of allergy in Japan. Fu-
ture plans entail taking the EECs to Europe
and expanding its utility to other diseases
like asthma.
CREATIVE SCIENTISTS,
SUCCESSFUL ENTREPRENEURS
When the company first emerged, it did
so with only a handful of employees. Four
years later, the staff count has reached
over 400. So what distinguishes Inflamax
from the rest? According to Dr. Salapatek,
it’s their scientific know-how. The team is
made up of professionals who are world
leaders in their area of expertise. Dr. Sala-
MAY 2016
H
business elite canada 63
